Insider Selling: OmniAb (NASDAQ:OABI) CFO Sells 9,301 Shares of Stock

OmniAb, Inc. (NASDAQ:OABI) CFO Kurt Gustafson sold 9,301 shares of the company’s stock in a transaction that occurred on Wednesday, February 18th. The shares were sold at an average price of $1.71, for a total transaction of $15,904.71. Following the sale, the chief financial officer directly owned 268,851 shares of the company’s stock, valued at approximately $459,735.21. This represents a 3.34% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

OmniAb Stock Performance

Shares of OABI remained flat at $1.71 during trading hours on Wednesday. 342,206 shares of the company were exchanged, compared to its average volume of 375,697. The company’s 50-day simple moving average is $1.89 and its 200-day simple moving average is $1.76. OmniAb, Inc. has a 52 week low of $1.22 and a 52 week high of $4.02. The company has a market capitalization of $246.17 million, a P/E ratio of -2.95 and a beta of 0.13.

Key OmniAb News

Here are the key news stories impacting OmniAb this week:

• Positive Sentiment: Institutional buying and concentrated ownership: several funds (Osaic, AQR, BNP Paribas, Cerity Partners, SG Americas) have recently increased or established stakes; institutional ownership is reported above 70%, which can support liquidity and longer-term stability. MarketBeat OABI page
• Neutral Sentiment: Analyst coverage is mixed: MarketBeat shows an average “Moderate Buy” rating and a mean price target near $6.67, but Weiss Ratings has a “sell (e+)” on the stock — a signal of divergent views that can keep trading range-bound. MarketBeat OABI page
• Neutral Sentiment: Key trading metrics: shares are being reported around $1.71 with a 50-day moving average (~$1.89) and 200-day (~$1.76); negative trailing P/E reflects current losses. These metrics frame risk/reward but do not convey near-term directional catalysts. MarketBeat OABI page
• Negative Sentiment: CEO Matthew W. Foehr sold shares on Feb. 17–18 (totaling 51,597 shares across two filings), reducing his stake modestly; filings: Feb. 18 sale. CEO Feb 18 Form 4 and Feb. 17 sale. CEO Feb 17 Form 4
• Negative Sentiment: CFO Kurt A. Gustafson sold shares on Feb. 17–18 (totaling 16,129 shares across two filings), trimming his holding by a few percent; filings: Feb. 18. CFO Feb 18 Form 4 and Feb. 17. CFO Feb 17 Form 4
• Negative Sentiment: Director Charles S. Berkman sold shares on Feb. 17–18 (totaling 16,663 shares across two filings), reducing his stake by a few percent; filings: Feb. 18. Director Feb 18 Form 4 and Feb. 17. Director Feb 17 Form 4

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the business. Osaic Holdings Inc. increased its position in OmniAb by 214.4% in the second quarter. Osaic Holdings Inc. now owns 14,247 shares of the company’s stock worth $25,000 after purchasing an additional 9,716 shares during the last quarter. AQR Capital Management LLC bought a new position in OmniAb during the first quarter valued at $25,000. BNP Paribas Financial Markets grew its stake in shares of OmniAb by 92.5% in the 3rd quarter. BNP Paribas Financial Markets now owns 21,721 shares of the company’s stock worth $35,000 after buying an additional 10,438 shares in the last quarter. Cerity Partners LLC increased its holdings in shares of OmniAb by 111.5% in the 2nd quarter. Cerity Partners LLC now owns 22,612 shares of the company’s stock worth $39,000 after buying an additional 11,919 shares during the last quarter. Finally, SG Americas Securities LLC raised its position in shares of OmniAb by 96.6% during the 4th quarter. SG Americas Securities LLC now owns 23,141 shares of the company’s stock valued at $43,000 after buying an additional 11,369 shares in the last quarter. 72.08% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of OmniAb in a report on Monday, December 22nd. Three investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $6.67.

OmniAb Company Profile

OmniAb, Inc (NASDAQ: OABI) operates as a biotechnology company specializing in the discovery and development of therapeutic antibodies. The company’s integrated antibody discovery platform combines proprietary transgenic animal models, in vitro screening, and in silico engineering to accelerate lead identification and optimization. OmniAb offers both fee-for-service collaborations and license agreements, enabling biopharmaceutical partners to leverage its suite of technologies for programs spanning oncology, immunology, and other therapeutic areas.

Founded in 2016 and headquartered in Seattle, Washington, OmniAb went public in May 2021.